Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have issued a buy recommendation and four have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $29.6667.

MPLT has been the subject of a number of research analyst reports. Lifesci Capital upgraded Maplight Therapeutics to a “strong-buy” rating in a research note on Thursday, May 14th. Wall Street Zen upgraded Maplight Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Wolfe Research reiterated an “outperform” rating and set a $30.00 price target on shares of Maplight Therapeutics in a research report on Monday, July 27th. Benchmark reiterated a “buy” rating on shares of Maplight Therapeutics in a research report on Monday, June 22nd. Finally, UBS Group cut shares of Maplight Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $52.00 to $13.00 in a research note on Monday, August 10th.

Insider Activity

In related news, insider James Woodruff Lillie sold 22,082 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $12.54, for a total value of $276,908.28. Following the transaction, the insider directly owned 202,380 shares of the company’s stock, valued at approximately $2,537,845.20. This trade represents a 9.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox acquired 15,620 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were purchased at an average price of $9.52 per share, with a total value of $148,702.40. Following the completion of the purchase, the director owned 15,620 shares in the company, valued at $148,702.40. This represents a ? increase in their position. The SEC filing for this purchase provides additional information. 3.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maplight Therapeutics

Institutional investors have recently bought and sold shares of the company. Fcpm Iii Services B.V. purchased a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $56,672,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at approximately $49,168,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at approximately $34,026,000. BlackRock Inc. acquired a new position in Maplight Therapeutics in the second quarter valued at approximately $36,741,000. Finally, Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the second quarter worth approximately $34,809,708,000.

Maplight Therapeutics Price Performance

Shares of MPLT stock opened at $11.21 on Monday. The stock’s 50-day moving average is $25.57 and its 200 day moving average is $24.29. Maplight Therapeutics has a 1-year low of $9.10 and a 1-year high of $40.43. The company has a market cap of $519.92 million and a P/E ratio of -0.26.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.08. On average, analysts anticipate that Maplight Therapeutics will post -5.12 EPS for the current year.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.